IL33 and cardiac hypertrophy: Inhibition of the interaction between IL-33 and tST2 leads to a reduction of myocardial fibrosis, cardiomyocyte hypertrophy, and apoptosis [8,9], while sST2 removes IL-33 from the circulation, promoting cardiac hypertrophy, fibrosis, and ventricular dysfunction [8].